Jan 10, 2022 / 03:30PM GMT
Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
Morning, everyone. Happy to introduce our next company. We have DexCom's CEO, Kevin Sayer, joining us now. And following up in the Q&A session, we'll also have Jereme Sylvain, the CFO of DexCom.
(Operator Instructions)
But for now, Kevin, I'm going to turn it over to you and join you in a little bit.
Kevin Ronald Sayer - DexCom, Inc. - Executive Chairman, CEO & President
Well, Robbie, thanks for having us again this year. We're going to start on Slide 3, and it's a great day for us. I want to start by emphasizing that DexCom still has, and we have tremendous opportunities ahead of us. I've been doing this for a long time with respect to diabetes and the story never changes.
Diabetes continues to grow, be a big problem and it never slows down. And consistently, DexCom has provided the best outcomes and solution across all diabetes. We have a lot of runway left in our U.S. market. While we've achieved a lot of penetration here, there's still plenty of
Dexcom Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers